+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atipamezole Market by Product Type, Application, End User, Therapeutic Area, Mode of Administration, Drug Class - Global Forecast 2025-2030- Product Image
Atipamezole Market by Product Type, Application, End User, Therapeutic Area, Mode of Administration, Drug Class - Global Forecast 2025-2030- Product Image
Sale

Atipamezole Market by Product Type, Application, End User, Therapeutic Area, Mode of Administration, Drug Class - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013931
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Atipamezole Market grew from USD 87.39 billion in 2023 to USD 98.03 billion in 2024. It is expected to continue growing at a CAGR of 12.86%, reaching USD 203.84 billion by 2030.

Atipamezole, an alpha-2 adrenergic receptor antagonist primarily used as a veterinary medicine to reverse the sedative effects of dexmedetomidine and medetomidine in animals, has a narrowly defined but significant scope in animal healthcare. Its necessity arises from its ability to quickly and effectively reverse sedation, thereby reducing recovery time and enhancing animal welfare, which is critical in veterinary surgical and diagnostic procedures. The application scope encompasses veterinary practices, veterinary hospitals, and research institutions where animal models are used. End-use entails veterinarians and researchers who demand rapid recovery from sedation to improve care outcomes.

Key growth factors driving the Atipamezole market include the rising number of pet adoptions, increasing awareness of pet health, and the growing adoption of advanced veterinary procedures that necessitate reversible sedation. The emergence of animal health NGOs and rising disposable income among pet owners provide additional market opportunities. Furthermore, advancements in veterinary diagnostics and surgical techniques enhance its application, offering potential growth avenues. Companies should focus on expanding geographical reach and collaborations with veterinary institutions to capitalize on emerging markets. Developing multi-use or combination drugs to maximize the therapeutic potential could be an area of valuable research and innovation.

Challenges in the Atipamezole market include its limited application specific to sedative reversal, potential adverse effects, and strict regulatory requirements governing animal pharmaceuticals that can impede market entry. Additionally, a relatively concentrated market with major players controlling substantial shares limits the entry of smaller companies. Innovation can be pivoted toward creating alternative delivery methods and minimizing adverse effects to broaden its appeal. Furthermore, enhancing pet insurance coverage for veterinary procedures might mitigate cost concerns for pet owners, potentially boosting market growth. Overall, aligning product development with universal veterinary policy standards and focusing on formulation innovations can ensure sustainable growth and competitive advantage.

Understanding Market Dynamics in the Atipamezole Market

The Atipamezole Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increase in awareness about the benefits of Atipamezole for veterinary use
    • Growth in the number of pets and rising expenditure on pet healthcare
    • Advances in veterinary medicine enhancing the demand for effective reversal agents
    • Surging demand for anesthesia reversal drugs driving Atipamezole market growth
  • Market Restraints
    • Potential side effects associated with atipamezole
  • Market Opportunities
    • Expansion of veterinary clinics and hospitals increasing the need for atipamezole
    • Government initiatives for animal health enhancing the use of atipamezole in treatment
  • Market Challenges
    • Stringent regulatory standards for approval of atipamezole

Exploring Porter’s Five Forces for the Atipamezole Market

Porter’s Five Forces framework further strengthens the insights of the Atipamezole Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Atipamezole Market

External macro-environmental factors deeply influence the performance of the Atipamezole Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Atipamezole Market

The Atipamezole Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Atipamezole Market

The Atipamezole Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Atipamezole Market

The Atipamezole Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atipamezole Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim GmbH, Ceva Santé Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Elanco Animal Health, Eli Lilly and Company, Huvepharma, IDEXX Laboratories, Inc., Kyoritsu Seiyaku Corporation, Merck & Co., Inc., Nestle Purina PetCare Company, Norbrook Laboratories, Orion Corporation, Ourofino Saúde Animal, Pfizer Inc., Phibro Animal Health Corporation, Vetoquinol SA, Virbac, and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Atipamezole Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Injectable
      • Human Use
      • Veterinary Use
    • Topical
      • Cream
      • Gel
      • Ointment
  • Application
    • Drug Overdose Management
    • Neurological Disorders
      • Alzheimer's Disease
      • Parkinson's Disease
    • Reversal of Sedation
      • Emergency Use
      • Post-Surgical
    • Treatment of Hypotension
      • Acute Hypotension
      • Chronic Hypotension
  • End User
    • Clinics
      • Inpatient Clinics
      • Outpatient Clinics
    • Homecare Settings
    • Hospitals
      • General Hospitals
      • Specialty Hospitals
  • Therapeutic Area
    • Cardiology
      • Congestive Heart Failure
      • Coronary Artery Disease
    • Neurology
      • Migraine
      • Seizures
    • Oncology
      • Chemotherapy
      • Radiation Therapy
  • Mode of Administration
    • Oral
      • Capsules
      • Liquids
      • Tablets
    • Parenteral
      • Intramuscular
      • Intravenous
    • Transdermal
      • Creams
      • Patches
  • Drug Class
    • Adrenergic Blocking Agents
    • Alpha-2 Adrenergic Antagonists
    • Antihypotensives
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in awareness about the benefits of Atipamezole for veterinary use
5.1.1.2. Growth in the number of pets and rising expenditure on pet healthcare
5.1.1.3. Advances in veterinary medicine enhancing the demand for effective reversal agents
5.1.1.4. Surging demand for anesthesia reversal drugs driving Atipamezole market growth
5.1.2. Restraints
5.1.2.1. Potential side effects associated with atipamezole
5.1.3. Opportunities
5.1.3.1. Expansion of veterinary clinics and hospitals increasing the need for atipamezole
5.1.3.2. Government initiatives for animal health enhancing the use of atipamezole in treatment
5.1.4. Challenges
5.1.4.1. Stringent regulatory standards for approval of atipamezole
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Atipamezole Market, by Product Type
6.1. Introduction
6.2. Injectable
6.2.1. Human Use
6.2.2. Veterinary Use
6.3. Topical
6.3.1. Cream
6.3.2. Gel
6.3.3. Ointment
7. Atipamezole Market, by Application
7.1. Introduction
7.2. Drug Overdose Management
7.3. Neurological Disorders
7.3.1. Alzheimer's Disease
7.3.2. Parkinson's Disease
7.4. Reversal of Sedation
7.4.1. Emergency Use
7.4.2. Post-Surgical
7.5. Treatment of Hypotension
7.5.1. Acute Hypotension
7.5.2. Chronic Hypotension
8. Atipamezole Market, by End User
8.1. Introduction
8.2. Clinics
8.2.1. Inpatient Clinics
8.2.2. Outpatient Clinics
8.3. Homecare Settings
8.4. Hospitals
8.4.1. General Hospitals
8.4.2. Specialty Hospitals
9. Atipamezole Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiology
9.2.1. Congestive Heart Failure
9.2.2. Coronary Artery Disease
9.3. Neurology
9.3.1. Migraine
9.3.2. Seizures
9.4. Oncology
9.4.1. Chemotherapy
9.4.2. Radiation Therapy
10. Atipamezole Market, by Mode of Administration
10.1. Introduction
10.2. Oral
10.2.1. Capsules
10.2.2. Liquids
10.2.3. Tablets
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.4. Transdermal
10.4.1. Creams
10.4.2. Patches
11. Atipamezole Market, by Drug Class
11.1. Introduction
11.2. Adrenergic Blocking Agents
11.3. Alpha-2 Adrenergic Antagonists
11.4. Antihypotensives
12. Americas Atipamezole Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Atipamezole Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Atipamezole Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
15.4.1. Exploring Merck & Co., Inc.'s market strategies and growth opportunities: a strategic analysis of vehicle safety product expansion
15.4.2. An in-depth analysis of Zoetis Inc.'s strategic advancements and market positioning amidst global expansion trends
List of Figures
FIGURE 1. ATIPAMEZOLE MARKET RESEARCH PROCESS
FIGURE 2. ATIPAMEZOLE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ATIPAMEZOLE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ATIPAMEZOLE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ATIPAMEZOLE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ATIPAMEZOLE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ATIPAMEZOLE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. ATIPAMEZOLE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ATIPAMEZOLE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ATIPAMEZOLE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ATIPAMEZOLE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ATIPAMEZOLE MARKET DYNAMICS
TABLE 7. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ATIPAMEZOLE MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ATIPAMEZOLE MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ATIPAMEZOLE MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ATIPAMEZOLE MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ATIPAMEZOLE MARKET SIZE, BY DRUG OVERDOSE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ATIPAMEZOLE MARKET SIZE, BY EMERGENCY USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ATIPAMEZOLE MARKET SIZE, BY POST-SURGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ACUTE HYPOTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CHRONIC HYPOTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ATIPAMEZOLE MARKET SIZE, BY INPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ATIPAMEZOLE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ATIPAMEZOLE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ATIPAMEZOLE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ATIPAMEZOLE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ATIPAMEZOLE MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ATIPAMEZOLE MARKET SIZE, BY SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ATIPAMEZOLE MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ATIPAMEZOLE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ATIPAMEZOLE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ATIPAMEZOLE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ATIPAMEZOLE MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ATIPAMEZOLE MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ADRENERGIC BLOCKING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ALPHA-2 ADRENERGIC ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL ATIPAMEZOLE MARKET SIZE, BY ANTIHYPOTENSIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. CANADA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. CANADA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 132. CANADA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 133. CANADA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. CANADA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. CANADA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 136. CANADA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 137. CANADA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. CANADA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 139. CANADA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. CANADA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 141. CANADA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. CANADA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 143. CANADA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CANADA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. CANADA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 146. CANADA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 147. CANADA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 148. CANADA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 151. MEXICO ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 152. MEXICO ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. MEXICO ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 155. MEXICO ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 156. MEXICO ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 158. MEXICO ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 160. MEXICO ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 161. MEXICO ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 162. MEXICO ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. MEXICO ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. MEXICO ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 166. MEXICO ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 167. MEXICO ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES ATIPAMEZOLE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC ATIPAMEZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. CHINA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. CHINA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 229. CHINA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 230. CHINA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. CHINA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. CHINA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 233. CHINA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 234. CHINA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. CHINA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 236. CHINA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. CHINA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. CHINA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 239. CHINA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 240. CHINA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 241. CHINA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. CHINA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 243. CHINA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 244. CHINA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 245. CHINA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. INDIA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. INDIA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 249. INDIA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. INDIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 251. INDIA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 253. INDIA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDIA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 255. INDIA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. INDIA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 257. INDIA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 258. INDIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 259. INDIA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 260. INDIA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. INDIA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. INDIA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 263. INDIA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 264. INDIA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. JAPAN ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 286. JAPAN ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 287. JAPAN ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. JAPAN ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 290. JAPAN ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 291. JAPAN ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 295. JAPAN ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 296. JAPAN ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 297. JAPAN ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. JAPAN ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. JAPAN ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 300. JAPAN ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 301. JAPAN ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 302. JAPAN ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 312. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 314. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 315. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 316. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 317. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 319. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 320. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 321. MALAYSIA ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 340. PHILIPPINES ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 341. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 351. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 352. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 353. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 354. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 355. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 356. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 357. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 358. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 359. SINGAPORE ATIPAMEZOLE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 360. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 361. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 362. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 363. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 364. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 365. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY REVERSAL OF SEDATION, 2018-2030 (USD MILLION)
TABLE 366. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY TREATMENT OF HYPOTENSION, 2018-2030 (USD MILLION)
TABLE 367. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 368. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 369. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 370. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 371. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 372. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 373. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 374. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 375. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 376. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 377. SOUTH KOREA ATIPAMEZOLE MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 378. SOUTH KOREA ATIPAMEZOLE MARKET S

Companies Mentioned

The leading players in the Atipamezole market, which are profiled in this report, include:
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health
  • Eli Lilly and Company
  • Huvepharma
  • IDEXX Laboratories, Inc.
  • Kyoritsu Seiyaku Corporation
  • Merck & Co., Inc.
  • Nestle Purina PetCare Company
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saúde Animal
  • Pfizer Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac
  • Zoetis Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 98.03 Billion
Forecasted Market Value ( USD ) by 2030 $ 203.84 Billion
Compound Annual Growth Rate12.8%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Atipamezole (CAS 104054-27-5) Global Market Research Report 2024 - Product Image

Atipamezole (CAS 104054-27-5) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Plumb's Veterinary Drug Handbook. Edition No. 10 - Product Image

Plumb's Veterinary Drug Handbook. Edition No. 10

  • Book
  • 1568 Pages
Veterinary Pharmaceuticals Market by Products, Animal Type, Mode of Administration, Indications, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Veterinary Pharmaceuticals Market by Products, Animal Type, Mode of Administration, Indications, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Ceftiofur Market by Delivery Form, Application, End Users, Distribution Channel - Global Forecast 2025-2030 - Product Image

Ceftiofur Market by Delivery Form, Application, End Users, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Animal Gastroesophageal Reflux Disease Market Size, Share & Trends Analysis Report By Product, By Animal (Companion, Livestock), By Mode, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Animal Gastroesophageal Reflux Disease Market Size, Share & Trends Analysis Report By Product, By Animal (Companion, Livestock), By Mode, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Market

Atipamezole is a drug used in animal pharmaceuticals to reverse the effects of sedatives and tranquilizers. It is commonly used in veterinary medicine to treat animals that have been sedated for medical procedures. Atipamezole is a synthetic alpha-2 adrenergic receptor antagonist, meaning it blocks the action of the neurotransmitter norepinephrine, which is responsible for the sedative effects of tranquilizers. It is available in both injectable and oral forms, and is typically administered shortly after the sedative has been given. Atipamezole is used in a variety of animal species, including cats, dogs, horses, and birds. It is also used in zoo animals, such as elephants and primates. The drug is generally well-tolerated and has few side effects. Atipamezole is manufactured by several companies, including Zoetis, Merck Animal Health, and Elanco Animal Health. It is also available from a number of generic manufacturers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.